Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. by Toniolo, Paolo et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Human chorionic gonadotropin in pregnancy and maternal risk 
of breast cancer. 
Authors: Toniolo P, Grankvist K, Wulff M, Chen T, Johansson R, Schock 
H, Lenner P, Hallmans G, Lehtinen M, Kaaks R, Wadell G, Zeleniuch-
Jacquotte A, Lundin E, Lukanova A 
Journal: Cancer research 
Year: 2010 Sep 1 
Volume: 70 
Issue: 17 
Pages: 6779-86 
DOI: 10.1158/0008-5472.CAN-09-4622 
 
Human Chorionic Gonadotropin in Pregnancy and Maternal Risk
of Breast Cancer
Paolo Toniolo1,2,3,4, Kjell Grankvist5, Marianne Wulff6, Tianhui Chen10, Robert
Johansson7, Helena Schock10, Per Lenner7, Göran Hallmans8, Matti Lehtinen11, Rudolf
Kaaks10, Göran Wadell9, Anne Zeleniuch-Jacquotte2,3, Eva Lundin5,*, and Annekatrin
Lukanova10,*
1Department of Obstetrics and Gynecology, NYU School of Medicine, New York, USA 2Department
of Environmental Medicine, NYU School of Medicine, New York, USA 3NYU Cancer Institute, NYU
School of Medicine, New York, USA 4Institute of Social and Preventive Medicine, University of
Lausanne, Lausanne, Switzerland 5Department of Medical Biosciences, University of Umeå, Umeå,
Sweden 6Department of Clinical Sciences, University of Umeå, Umeå, Sweden 7Department of
Radiation Sciences, University of Umeå, Umeå, Sweden 8Department of Public Health and Clinical
Medicine, University of Umeå, Umeå, Sweden 9Department of Clinical Microbiology, University of
Umeå, Umeå, Sweden 10Division of Cancer Epidemiology, German Cancer Research Center,
Heidelberg, Germany 11University of Tampere, Tampere, Finland
Abstract
Full-term pregnancies are associated with long-term reductions in maternal risk of breast cancer, but
the biological determinants of the protection are unknown. Experimental observations suggest that
human Chorionic Gonadotropin (hCG), a major hormone of pregnancy, could play a role in this
association. A case-control study (242 cases, 450 controls) nested within the Northern Sweden
Maternity Cohort included women who had donated a blood sample during the first trimester of a
first full-term pregnancy. Total hCG was determined on Immulite 2000 analyzer. Odds ratios (OR)
and 95% confidence intervals (CI) were estimated through conditional logistic regression. Maternal
breast cancer risk decreased with increasing hCG (upper tertile OR, 0.67; CI, 0.46-0.99) especially
for pregnancies before age 25 (upper tertile OR, 0.41; CI, 0.21-0.80). The association diverged
according to age at diagnosis: risk was reduced after age 40 (upper tertile OR: 0.60; CI, 0.39-0.91)
and appeared to increase before age 40 (upper tertile OR: 1.78; CI, 0.72-4.38). Risk was reduced
among those diagnosed 10 years or longer after blood draw (upper tertile OR, 0.60; CI, 0.40-0.90),
but not so among those diagnosed within 10 years (upper tertile OR, 4.33; CI, 0.86-21.7). These
observations suggest that the association between pregnancy hCG and subsequent maternal risk of
breast cancer is modified by age at diagnosis. While the hormone appears to be a determinant of the
reduced risk around or after age 50, it might not confer protection against, or it could even increase
the risk of, cancers diagnosed in the years immediately following pregnancy.
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Introduction
Women who have carried to term at least one pregnancy experience approximately a one-fourth
reduction in their lifetime risk of breast cancer, as compared to nulliparous, which is stronger
the younger the age at first pregnancy (1). Multiparity (2) and extended breastfeeding (3) further
enhance this protection. Ample epidemiological evidence supports the association consistently
across populations in all continents (1), but not all women benefit from the protection. Some,
especially those who delay first pregnancy beyond age 30, may experience a substantial
increase in the risk of breast cancer that peaks after about 5-7 years and slowly declines for up
to 15 years following pregnancy (4).
In spite of the weight of epidemiological evidence, our understanding of the biological
determinants of the effect of pregnancy on breast cancer, both the lifetime protection and the
transient post-pregnancy increase, remain sketchy. An extensive literature on mammary
carcinoma in rodents shows unequivocally not only that pregnancy, especially when occurring
early in life, inhibits carcinogen-induced tumors, but also that the same effect could be achieved
through the administration of specific hormones of pregnancy, including estradiol plus
progesterone and human chorionic Gonadotropin (hCG), to virgin animals (5-7). In line with
these observations, a large population-based case-control study in California (8) reported that
young women who had been treated with daily injections of hCG for weight reduction were at
considerably reduced risk of breast cancer, an association particularly evident among the
nulliparous. Thus, the combined human and experimental evidence suggests that the hormones
that are of relevance to the normal progression of pregnancy are also relevant to the profound
physiological changes in the breast that occur during pregnancy. Such hormonally induced
changes might be important in protecting the gland from carcinogenic transformation.
To our knowledge, only a preliminary study that served to set the stage for the present research
has addressed the association of maternal breast cancer risk and circulating hCG during
pregnancy (9). The preliminary study, a case-control of 173 cases and 254 controls nested in
the same prospective maternity cohort in North Sweden as the present study, suggested that
women in the upper tertile of first trimester hCG were at reduced risk of breast cancer, a
reduction especially evident among those who were past the median lag-time of 14 years after
pregnancy (OR, 0.53: CI, 0.27-1.03). However, because the study included a mix of
primiparous and non-primiparous subjects at baseline blood draw, separating the effect of age
at first birth from that of parity on the hCG-breast cancer risk association was not possible.
The current study addresses the hypothesis that lifelong maternal breast cancer risk is reduced
in women who experience elevations in circulating hCG during the first trimester of a first full-
time pregnancy, a protective effect expected to be stronger the younger the age of the mother
at pregnancy. The hypothesis is rooted in seminal experimental observations showing that the
strong differentiating potential of hCG on mammary cells would drive the formation of a
complex, well differentiated glandular structure refractory to carcinogenic insults provided that
exposure to the hormone (through a healthy pregnancy or chemo-intervention) precedes
exposure to carcinogens capable of initiating still undifferentiated breast cells (10).
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Materials and Methods
Study design and population
Study subjects were part of the North Sweden Maternity Cohort at the University of Umeå,
Sweden, established in 1975 and described previously (9,11). The cohort includes residents of
one of the four northernmost counties of Sweden recruited while attending a Maternity Care
Unit, run by the Swedish National Health Care System, providing pre- and post-natal care free
of charge to all pregnant women. Blood samples are drawn from all patients during the latter
part of the first trimester, or the early weeks of the second. Blood sera are shipped frozen to a
central repository at the University Hospital in Umeå where laboratory analyses are performed
for clinical purposes. Leftover specimens are stored at −20°C and preserved for research. The
cohort’s biological bank contains approximately 110,000 serum samples from approximately
83,000 women.
In a case-control study nested within the cohort, of interest were cohort members with blood
specimens drawn during a primiparous pregnancy leading to the delivery at full term
(pregnancy lasting > 259 days) of a singleton live or stillborn child. In the maternity cohort
database, available information was limited to personal identity number, name, sample serial
number and location of sampling. The identification and selection of eligible case and control
study subjects required a multi-step approach involving record linkages with nationwide
databases made possible by the availability for all cohort subjects of the unique 10-digit
personal identification number assigned to every person born in, or legally resident of, Sweden.
The first record linkage was performed with the Swedish Birth Register, a nationwide
information system gathering data from all standardized medical records used in every maternal
care and delivery units since 1973 (12). Over 99% of all births are registered and the quality
and completeness of information is excellent. Through this linkage, the information available
was expanded to include parity, date of each delivery and gestational age at birth. All
primiparous subjects 40 or younger at blood draw who had given birth to a full-term live or
stillborn singleton child were included in the study file.
The next record linkage was performed with the Swedish Cancer Registry to identify
potentially eligible breast cancer cases and exclude women ineligible to be controls from the
study file. The Cancer Registry, maintained by the Board of Health and Welfare, was founded
in 1958 and covers the whole Swedish population with completeness of registration estimated
to be 96.3% (13). Of interest were women first diagnosed with invasive epithelial breast cancer
during the interval spanning from one year after delivery until June 8, 2007. A total of 315
potentially eligible case subjects were identified. Suitable serum samples were available for
289 (92%) of the cases, including 57 (18%) who were part of our previous report (8), and those
were considered for the current study. As reported previously (8), excluded were also all
samples collected after January 1, 1988, because the stability and quality of hormonal
measurements on such samples was frequently compromised as a consequence of changes in
specimen preparation procedures that the clinical laboratory had adopted on that date. There
was no evidence of degradation for samples collected prior to this time, during which the vast
majority of specimens from breast cancer cases and controls included in the study had been
drawn. Samples judged to be of poor quality at inspection (severe hemolysis, discoloration)
and those containing less than 700 μl of serum were excluded from study.
For each case (index case), potential controls were selected at random among cohort members
in the study file who were alive and free of cancer at the time of the case’s diagnosis. Two
controls were sought for each case, individually matched on age at sampling (± 6 months) and
date of sampling (± 3 months). Lists of up to 14 potential controls were drawn for each case.
New controls were selected for the 57 cases included in our preliminary report.
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For each case and four of her potential controls, a full copy of the relevant maternity and
delivery records was requested from the pertinent hospital in order to estimate gestational day
at blood draw from the dates of blood draw and last menstrual period and to retrieve additional
information for the study. Of the 1,504 requested (289 cases, 1,210 controls), 1,359 were
obtained (88% of the cases, 91% of the controls). If information on date of blood draw was
missing, gestational age at blood draw was greater than 120 days, or there was no biological
specimen available for assay, the subject was excluded (6 cases, 120 controls). If the 4 initial
controls selected for a given case were found to be ineligible, the records of 4 new potential
controls were requested until at least one eligible control was identified, or all potential controls
selected initially were found to be ineligible. If a matched set included a case and at least one
individually matched control, the remainder of the information from the medical records was
abstracted, which included: menstrual cycle characteristics and contraceptive methods used
before index pregnancy, smoking, maternal weight and height at enrollment, treatments for
infertility or other hormonal treatments during pregnancy, pregnancy conditions, including
pre-eclampsia and hypertension, child’s gender, weight, length and placental weight. Sixteen
subjects (4 cases, 12 controls) who had been treated with hormones during pregnancy, 3 cases
without eligible controls and all controls for ineligible cases were excluded. In total, 242 cases
and 450 controls were included in the study.
This study was approved annually by the Regional Ethics Committee of Umeå, Sweden. All
information allowing the identification of human subjects was removed from the study database
used for data preparation, editing and statistical analyses. Serum specimens used in laboratory
analyses were labeled using anonymous codes.
Laboratory analyses
Total hCG and cotinine were measured in the laboratory of Clinical Chemistry, University
Hospital in Umeå, Sweden, where technicians and their supervisors were unaware of any
information concerning the specimens, including exposure and blind quality control status.
Cotinine, a reliable indicator of recent exposure to tobacco, was used to complement medical
record information, as smoking during pregnancy is known to lower hCG (8,13). Serum
specimens of individually matched case and control subjects were always included in the same
laboratory run. In addition to routine laboratory quality controls, a pool of serum from the
cohort was created at the beginning of the study and 2 aliquots, undistinguishable from the test
samples were inserted in each laboratory run. Both total hCG and cotinine were quantified by
solid-phase competitive chemiluminescence assays on an Immulite 2000 Siemens analyzer.
For hCG, the intra- and inter-run coefficients of variation estimated from analyses of laboratory
quality controls spiked with 44 mIU/mL hCG were 1.8% and 13.7%, whereas those spiked
with 427 mIU/mL hCG were 7.4% and 7.2%, respectively. The total (intra- + inter-batch)
coefficient of variation based on the quality controls from the blind pool was 5.0 percent. The
intra- and inter-batch coefficients of variation for cotinine were 5.5% and 9.9% at 18 ng/mL
concentration and 5.6% and 8.5% at 60 ng/mL, respectively.
Statistical Analysis
Inter-individual hCG concentrations varied considerably during the gestational age of interest
showing a sharp tendency to increase until around day 60 and decreasing progressively
thereafter (Figure 1). Individual matching for gestational day would have been nearly
impossible to achieve since it would have required obtaining birth delivery records from a
much larger pool of potential controls in order to identify two for each set matching precisely.
Therefore, in all statistical analyses the variability in hCG was taken into account following
the approach of Richardson and Coll. (9,14). In summary, prior to analyses, original hCG values
were naturally log-transformed to limit heteroscedasticity. The mean curve of hCG variation
was estimated based on all data points using local linear regression (15), a nonparametric
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smoothing technique that employs weighted regression and uses specific subsets of the data to
estimate the curve at each point. hCG values for each study subject were computed as the
difference (residual) between the assay value and the estimated mean determined for the day
of gestation when the sample was drawn. The term “adjusted” hCG refers to hCG residuals
and not to the original measured values. There were no outliers exceeding 3 times the inter-
quartile range of concentrations.
Pearson correlation coefficients were used to relate adjusted hCG concentrations to specific
characteristics of interest (e.g., age, height, weight). Subgroup differences in adjusted hCG
(e.g., child’s gender, maternal smoking) were examined among controls using Generalized
Linear Models. Kappa statistic was used to compare categorical values of reported maternal
smoking at baseline and measured cotinine concentrations.
Mixed effect models with fixed effect for case-control status and maternal age and random
effect for matched set were used to compare adjusted hormone levels in cases and controls.
The conditional logistic regression model was used to calculate odds ratios (OR) and
corresponding 95% confidence intervals (CI) associated with increasing adjusted hCG. In
analyses utilizing the entire study population, subjects were classified in tertiles using the
frequency distribution of the controls. Tests for trend were computed by treating adjusted hCG
concentrations as ordered categorical variables quantitatively scored as ‘0’, ‘1’ and ‘2’ for
tertiles 1 to 3, respectively. Likelihood ratio tests were used to assess statistical significance.
Additionally, risk estimates were calculated on continuous scale of adjusted hCG for sub-group
analyses with small number of cases. The ORs correspond to a change of 1 natural-log-
transformed unit of hCG, or a ~ 2.7 change in hCG. Associations of breast cancer with adjusted
hCG were explored within strata of age at blood sampling (< 25, 25-30, ≥ 30), age at cancer
diagnosis (<40, 40–50, ≥50) and lag time between blood donation and date of diagnosis of the
index case (<10, 10-15, 15-20 and ≥20; and <10 vs. ≥10). Formal tests of heterogeneity between
the odds ratios in different subgroups were based on chi-square statistics, calculated as the
deviations of logistic regression coefficients observed in each of the subgroups, relative to the
overall regression coefficient (16). Potential confounders considered were maternal height,
weight, self-reported smoking at blood donation, cotinine concentrations, baby’s height,
weight, gender, placental weight, and parity by index date (cancer diagnosis). For inclusion in
final models, a confounder had to alter point estimates by 10% or more. All tests of statistical
significance were two-sided and considered significant if P-values were < 0.05.
Results
Table 1 reports relevant characteristics of the study population. Mean age at sampling was 27
for both cases and controls (range, 16.7-39.2). Blood had been drawn between the 8th and
14th gestational week for 81 percent of both cases and controls, before the 8th week for 15
percent and after the 14th week for 4 percent. Mean gestational day at sampling was 70.8 for
cases and 70.3 for controls. Mean age at diagnosis was 45.5 years (range, 25.5- 62.7). Most of
the cases (76 percent) had been diagnosed before age 50. Mean lag time between blood draw
and cancer diagnosis was 18.5 years (range, 2.7- 30.5). The two groups were highly comparable
on all characteristics.
Among controls, adjusted hCG concentrations were inversely correlated with maternal weight
(r= −0.14, p=0.003), were lower in mothers smoking while pregnant than in non-smokers
(−0.119 vs. 0.0998 mIU/mL; p<0.0001) and in those carrying a male (−0.056 vs. 0.127,
p<0.0001). There was an excellent correspondence between reported smoking and cotinine
(cutoff, 25 ng/mL) (Kappa=0.84). Adjusted hCG was lower in cases than in controls (−0.03
vs 0.03; p < 0.098) corresponding to original concentrations at gestational day 70 of 94,080
and 97,416 mIU/mL, respectively. The results of conditional logistic regression analyses are
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reported in Table 2. In analyses including all case-control sets, there was a 33 percent decrease
in risk of breast cancer with increasing adjusted hCG (upper tertile OR, 0.67; CI, 0.46-0.99;
ptrend, 0.04). In sub-group analyses according to age at hCG measurement, the inverse
association appeared to be limited to those whose blood was drawn at young age (upper tertile
OR, 0.41; CI 0.21-0.80; ptrend, 0.01), but the null hypothesis of homogeneity between groups
was not rejected (p =0.09).
In sub-group analyses with cutoff at age at diagnosis 40 years (Table 2) the risk of maternal
breast cancer associated with relative elevations of adjusted hCG appeared to diverge
substantially between the two groups (pheterogeneity=0.03), with markedly reduced risk among
those in the older group (upper tertile OR, 0.60; CI, 0.39-0.91; ptrend, 0.01) and increased risk
in the younger group (upper tertile OR, 1.78; CI, 0.72-4.38; ptrend, 0.20). The association
between hCG and breast cancer risk appear to differ according to lag-time between sampling
and date of diagnosis of index cases (pheterogeneity =0.02) with high risk among those diagnosed
within 10 years (upper tertile OR, 4.33; CI, 0.86-21.7) and marked risk reduction among those
with a longer lag-time (upper tertile OR, 0.60; CI, 0.40-0.90). Note that the <10 years group
included only 25 cases.
Table 3 reports on analyses performed on a continuous scale within subgroups of age at
sampling, age at diagnosis and lag-time to diagnosis. The strong inverse risk association with
increasing concentrations of adjusted hCG when sampled at young age (<25) persisted (OR,
0.52; CI, 0.29-0.94) and was also present in analyses limited to those >40 at diagnosis (OR,
0.43; CI, 0.21-0.87) and those with lag-time >10 years between blood draw and diagnosis (OR,
0.45; CI, 0.24-0.84). Within groups of age at diagnosis (< 40, 40-49 and ≥ 50) there was
evidence of progressive change in risk from relatively elevated in the youngest group (OR,
1.79; CI, 0.76-4.18) to markedly reduced in the oldest (OR, 0.37; CI, 0.16-0.88). Within groups
of increasing lag-time (<10, ≥10 years), the risk was substantially reduced within the longer
lag-time group (OR, 0.61; CI, 0.42-0.90), but not within the shorter where, on the contrary,
there was evidence that the risk could be somewhat increased (OR, 8.72; CI, 1.50-50.78). Age
at cancer diagnosis and lag-time between sampling and diagnosis were highly correlated
(r=0.73) and there was no evidence of effect modification between the two time-dependent
covariates.
Adjustments for reported smoking, maternal weight and height, placental weight, child’s
weight, length and gender, and parity by index date of diagnosis did not influence the above
associations. Exclusion of study subjects whose blood had been drawn beyond gestational day
98 (12 cases, 34 controls) and of those who had been included in the preliminary study (57
cases) had no appreciable effect.
Discussion
This study shows that hCG - one of the key hormones of pregnancy – may play a major role
in the long established, but biologically poorly understood, lifetime protection that a pregnancy
affords the mother. Women who had comparatively elevated concentrations of hCG in serum
drawn during the first trimester of a primiparous pregnancy experienced a 30 percent reduction
in the risk of breast cancer.
These observations are in line with the study’s hypothesis that hCG plays an important role in
conferring protection against breast cancer among women who experience their first delivery
early in life. The nulliparous breast is especially susceptible to toxicants and carcinogens
(17,18), which could lead to transformations in immature epithelial cells that in turn can become
the site of cancer initiation, as shown in animal experiments (19,20). The timely differentiation
of immature mammary cells following a pregnancy at early age would prevent the initiation
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of cancer (21) owing to hCG’s strong growth inhibitory, pro-apoptotic, anti-proliferative and
tumor suppressor activity (22) .
The most striking association pertains to the evident inverse association with increasing
concentrations of hCG for maternal cancers diagnosed after age 40, which becomes
considerably stronger after age 50, whereas elevated hCG appears to have no effect, or perhaps
even increase the risk of cancer diagnosed at young age and/or within 10 years after a first full-
term pregnancy. Even though a threshold effect rather than a dose-response model could always
be argued, in our view such findings are of extraordinary interest in that they suggest that while
in most women the powerful hormonal actions of hCG that pertain to the physiological
maturation of the breast exert a lasting beneficial effect in protecting the gland from cancer, in
some the same events do not confer any protection, or might even be associated with increased
risk of cancer at young age. It is possible that among the latter the hormone interacts with other
factors, such as individual genetic susceptibility, physiologically altered immunocompetence
of pregnancy, exposure to environmental and/or infectious agents, or pre-existing pre-
cancerous lesions (e.g., somatic mutations) hastening the early emergence of an invasive
cancer.
The study is prospective in design, a characteristic that excludes reverse-causation, or the
presence of an as yet undetected cancer being the cause of hCG alterations in pregnancy. A
prominent feature is that the study included exclusively women who were primiparous at the
time of blood drawing and whose pregnancy was carried out to full-term (37 or more weeks
of gestation). Because full-term pregnancies beyond the first are associated with additional
reduction in risk and, more importantly, hormone concentrations lower than in the first (23,
24), the inclusion of non-primiparous subjects would have rendered extremely difficult, if not
impossible, to disentangle the effect of a first pregnancy from that of subsequent ones, an issue
which should be addressed in specifically designed projects. Additionally, in statistical
analyses a woman’s full pregnancy history prior to cancer diagnosis was taken into account
without any evident influence on point estimates. Cases and controls were tightly matched for
age and date of blood draw and detailed information on covariates was secured through the
retrieval of individual medical records from the hospital of delivery, supplemented through
record linkages with high-quality nationwide registries.
Some major limitations should be considered. First, the temperature in the facility where serum
specimens had been kept in storage was relatively high (−20°C). Evidence that degradation
hadn’t occurred comes from observing that the distribution of original hCG measurements
according to gestational age closely reflected what would be expected from clinical experience
(Figure 1). Also reassuring was that original hCG concentrations were not correlated with
length of time in storage in cases and in controls (r=0.04 and 0.07, respectively). Second,
information on gestational age, a critically important piece of information, was estimated with
some degree of approximation. It is therefore possible that adjusted hCG levels were subject
to error in measurement. However, error would be expected to be non-differential with respect
to case/control status and therefore would most likely lead to an attenuation of relative risk
estimates. Third, the association of hCG with breast cancer may differ according to intrinsic
tumor subtypes (luminal, HER2-positive, basal and normal), an information that was not
available for the vast majority of study subjects. Indeed, the association of breast cancer risk
with reproductive risk factors has been shown to vary by subtype (25,26), including inverse
association with parity and age at first birth for hormone receptor-positive tumors and no
association with hormone receptor-negative tumors. Finally, the strong correlation between
age at diagnosis of index cases and lag time between pregnancy and date of index diagnosis
precluded meaningful analyses of interaction between these two time-dependent covariates.
Therefore, it was not possible to determine whether these two important variables were
independently associated with risk or whether only one of them mattered and the association
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with the other was entirely attributable to the high correlation. The study was based on a single
measurement at a single point in time in the course of a first pregnancy, a further potential
limitation. It should be considered, however, that hCG is detectable virtually exclusively in
pregnancy and that the hormone exerts a powerful stimulus inducing a profound differentiation
of the breast that transforms the immature, nulliparous breast in a mature organ (22). It has
been shown that there is a rather strong correlation between hCG concentrations in consecutive
pregnancies (r=0.42). In studies of Down syndrome, a condition characterized by extremely
elevated hCG, high hCG concentrations during a pregnancy are 3-times more likely to be
associated with similarly high levels in consecutive pregnancies (27). Thus, the early part of a
first full-term pregnancy is quite reasonably the most relevant period to relate hCG
concentrations to long-term risk.
A final comment concerns the appropriateness of the laboratory assay employed in the study
to measure hCG. The assay quantifies total hCG, including but not limited to the regular (or
intact) isoform, which predominates in the first trimester of all normal pregnancies. Two of
the hCG variants, the hyperglycosylated regular and hyperglycosylated free β-subunit have
been shown to possess important physiological functions distinct from that of regular hCG
(27). The hyperglycosylated variants have a fundamental autocrine role in regulating invasion
of the myometrium at implantation in addition to strong anti-apoptotic and pro-angiogenetic
properties. Therefore, it could not be ruled out that the excess risk observed among women
who develop early breast cancer might be in part related to exposure to a pattern of elevated
circulating hCG isoforms that is different from that associated with reduced risk of cancer
arising at older ages.
This is the first epidemiological study reporting evidence that elevations in circulating hCG
during the first trimester of a primiparous, full-term pregnancy completed at early age may be
an important determinant of the long noted, lasting protection against maternal breast cancer
that an early pregnancy affords the mother. In the past century or so, in all populations, age at
first pregnancy has progressively been delayed and the average number of children per woman
reduced (28) even though large differences remain between populations and social groups.
While the societal and economic forces that are at the roots of such profound, rapid changes
are unlikely to be modifiable, a better understanding of the factors mediating this protective
association could ultimately lead to the development of chemo-preventive interventions
seeking to mimic nature’s plans.
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Table 1
Umeå, Sweden, 1975-2008. Selected characteristics of study subjects: means (standard deviation) or frequencies
(percentage)
Characteristics Cases(242)
Controls
(450)
Maternal age at sampling 27 (4.2) 27 (4.1)
Gestational day 71 (14.5) 70 (14.1)
Age at diagnosis 46 (6.4)
Time from blood draw to diagnosis
(years) 19 (6.0)
Primi-gravida 200 (83%) 354 (79%)
Maternal weight at enrolment (kg) 61 (8.3) 62 (9.5)
Maternal height at enrolment (cm) 165 (5.6) 165 (5.7)
Mothers reporting smoking at enrolment* 74 (31%) 119 (27%)
Cotinine ≥ 25 ng/mL 87 (36%) 142 (32%)
Child male gender 133 (55%) 232 (52%)
Child weight at birth (g) 3,475(439.8)
3,444
(458)
Child length at birth (cm) 50 (2.2) 50 (2.0)
Placental weight (g) ** 577 (119.5) 579 (116.7)
Parity ***
  1 59 (24%) 84 (19%)
  2 127 (52%) 232 (52%)
  >2 56 (23%) 134 (30%)
*
235 cases, 435 controls
**
206 cases, 385 controls
***
Number of children born before index date of cancer diagnosis
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Table 3
Umeå, Sweden, 1975-2008. Relative risk change in one unit of adjusted hCG concentrations
Cases / Controls OR (continuous) p pHomo
By age at sampling
< 25 80 / 149 0.52 (0.29 - 0.94) 0.03 0.14
25-30 110 / 209 1.10 (0.65 - 1.88) 0.72 .
≥ 30 52 / 92 0.55 (0.21 - 1.46) 0.23 .
By age at diagnosis
< 40 43 / 78 1.79 (0.76 - 4.18) 0.18 0.04
40-50 142 / 271 0.71 (0.44 - 1.13) 0.15 .
≥ 50 57 / 101 0.37 (0.16 - 0.88) 0.02 .
By lag time between sampling and diagnosis
< 10 25 / 45 8.72 (1.50 - 50.78) 0.02 0.04
10-15 31 / 56 0.65 (0.23 - 1.82) 0.42 .
15-20 82 / 153 0.53 (0.27 - 1.02) 0.06 .
≥ 20 104 / 196 0.67 (0.39 - 1.14) 0.14 .
< 10 25 / 45 8.72 (1.50 - 50.78) 0.02 0.004
≥ 10 217 / 405 0.61 (0.42 - 0.90) 0.01 .
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